Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of carbohydrate tumor markers and inflammation-based markers in metastatic or recurrent gastric cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

We examined the relationship between hematological parameters and clinicopathologic significance in metastatic or recurrent gastric cancer (MRGC) patients, and construct a prognostic index for MRGC patients. We retrospectively reviewed the medical records of 439 patients with MRGC. Tumor markers, inflammation-based markers such as mGPS (which combines CRP and albumin concentrations), NLR, PLR and other hematological parameters were observed in the study. CA125 was more frequently positive with peritoneal recurrence, and CEA was more frequently positive in patients with liver metastases. In the univariate analysis of survival, the following variables were associated with shorter overall survival (OS): male, previous pathology such as nerves invasion and vessel invasion, elevated CEA, CA72-4, CA125 and CA19-9, and inflammation-based variables such as Alb, CRP, mGPS, PLR, NLR, Hb, LDH, AchE and AKP. In the multivariate analysis, mGPS, CEA and CA125 were independent prognostic factors for OS. An exploration of the potential prognostic index model including the three independent factors was carried out, MSTs for the low-, moderate- and high-risk groups were 12, 10.5 and 5 months. Elevated serum CEA, CA125 and mGPS in patients with MRGC are independent negative predictor of prognosis. And the prognostic index was constructed to predict prognosis of MRGC patients more accurately.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, González JR, Gratacòs M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, Zhang J, Zerjal T, Zhang J, Armengol L, Conrad DF. Global variation in copy number in the human genome. Nature. 2006;444(7118):444–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Lim ST, Hee SW, Quek R, Lim LC, Yap SP, Loong EL, Sng I, Tan LH, Ang MK, Ngeow J, Tham CK, Ngo L, Tan MH, Tao M. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Eur J Haematol. 2008;80(1):55–60.

    PubMed  Google Scholar 

  3. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Matsuura I, Yamaue H, Tanimura H. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res. 2001;61(16):6158–62.

    CAS  PubMed  Google Scholar 

  4. Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, Maruyama M. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy inpatients with advanced gastric cancer. Jpn J Clin Oncol. 1999;29(11):550–5.

    Article  CAS  PubMed  Google Scholar 

  5. Cetin B, Atalay C, Aslan S, Babacan B, Hatipoğlu C, Akinci M, Cetin A. Peritoneal carcinoembryonic antigen level for predicting locoregional and distant spread of gastric cancer. Surg Today. 2005;35(11):919–24.

    Article  CAS  PubMed  Google Scholar 

  6. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, Rake B, Space S, Westrick B, Schoemaker H, Zurawski VR Jr. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983;29(3):549–52.

    PubMed  Google Scholar 

  7. Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000;16(3–4):105–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Chen XZ, Zhang WK, Yang K, Wang LL, Liu J, Wang L, Hu JK, Zhang B, Chen ZX, Chen JP, Zhou ZG, Mo XM. Correlation between serum CA72-4 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep. 2012;39(9):9031–9.

    Article  CAS  PubMed  Google Scholar 

  9. Lai IR, Lee WJ, Huang MT, Lin HH. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology. 2002;49(46):1157–60.

    PubMed  Google Scholar 

  10. Haglund C, Kuusela P, Roberts P, Jalanko H. Tumour marker CA 125 in patients with digestive tract malignancies. Scand J Clin Lab Invest. 1991;51(3):265–70.

    Article  CAS  PubMed  Google Scholar 

  11. Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2011;15(2):154–61.

    Article  PubMed  Google Scholar 

  12. Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, Lee CK. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer. 2013;109(1):147–53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.

    Article  PubMed  Google Scholar 

  14. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007;73(3–4):215–20.

    Article  PubMed  Google Scholar 

  15. Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, Kim HJ. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013;13:350. doi:10.1186/1471-2407-13-350.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet–lymphocyte ratio. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2008;12(8):1422–8.

    Article  Google Scholar 

  17. Jackson C, Cunningham D, Oliveira J, Group EGW. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):34–6.

    PubMed  Google Scholar 

  18. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther. 2008;25(10):1075–84.

    Article  PubMed  Google Scholar 

  19. Victorzon M, Haglund C, Lundin J, Roberts PJ. A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer. Eur J Surg Oncol. 1995;21(4):379–84.

    Article  CAS  PubMed  Google Scholar 

  20. Gaspar MJ, Arribas I, Coca MC, Díez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol. 2001;22(5):318–22.

    Article  CAS  PubMed  Google Scholar 

  21. Marrelli D, Roviello F, DeStefano A, Farnetani M, Garosi L, Messano A, Pinto E. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology. 1999;57(1):55–62.

    Article  CAS  PubMed  Google Scholar 

  22. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001;181(1):16–19.

    Article  CAS  PubMed  Google Scholar 

  23. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.

    Article  CAS  PubMed  Google Scholar 

  24. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother CII. 2009;58(1):15–23.

    Article  CAS  PubMed  Google Scholar 

  25. Liao W, Zhang J, Zhu Q, Qin L, Yao W, Lei B, Shi W, Yuan S, Tahir SA, Jin J, He S. Preoperative neutrophil-to-lymphocyte ratio as a new prognostic marker in hepatocellular carcinoma after curative resection. Transl Oncol. 2014;7(2):248–55.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–4.

    Article  CAS  PubMed  Google Scholar 

  27. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol. 2000;85(11):896–9. doi:10.1002/ajh.21849.

    Article  Google Scholar 

  28. Hirashima M, Higuchi S, Sakamoto K, Nishiyama T, Okada H. The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with earlygastric cancer. J Cancer Res Clin Oncol. 1998;124(6):329–34.

    Article  CAS  PubMed  Google Scholar 

  29. Liu H, Du X, Sun P, Xiao C, Xu Y, Li R. Preoperative platelet–lymphocyte ratio is an independent prognostic factor for resectable colorectal cancer. Nan Fang Yi Ke Da Xue Xue Bao J South Med Univ. 2013;33(1):70–3.

    Google Scholar 

  30. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, Park KJ, Roh MS, Kim SG, Kim HJ, Lee JH. Clinical significance of preoperative neutrophil–lymphocyte versus platelet–lymphocyte ratio in patients with operable colorectal cancer. Biomark Biochem Indic Expo Response, Susceptibility Chem. 2012;17(3):216–22.

    CAS  Google Scholar 

  31. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DSJ, Foulis AK, Horgan PG, McMillan DC. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study (Oxford, England: 1990). Eur J Cancer. 2011;47(17):2633–41.

    Article  PubMed  Google Scholar 

  32. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94(5):637–41.

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O’Reilly DSJ, Foulis AK, Horgan PG, McMillan DC. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, Foulis AK, Horgan PG, McMillan DC. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633–41.

    Article  PubMed  Google Scholar 

  35. Xia WX, Ye YF, Lu X, Wang L, Ke LR, Zhang HB, Roycik MD, Yang J, Shi JL, Cao KJ, Guo X, Xiang YQ: The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy.(2013) PLoS One; 8(10):e76958. doi:10.1371/journal.pone.0076958. eCollection 2013.

  36. Baba H, Kuwabara K, Ishiguro T, Hatano S, Matsuzawa T, Fukuchi M, Kumagai Y, Ishibashi K, Mochiki E, Ishida H. C-reactive protein as a significant prognostic factor for stage IV gastric cancer patients. Anticancer Res. 2013;33(12):5591–5.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was funded by grants from the National Natural Science Foundation of China (Grant No. 81000980, 81220108023, 81370064), Jiangsu Provincial Program of Medical Science (BL2012001) and the distinguished young investigator project of Nanjing (JQX12002).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, 210008, China

    Qing Wang, Yang Yang, Ya-ping Zhang, Zhengyun Zou, Xiaoping Qian, Baorui Liu & Jia Wei

Authors
  1. Qing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ya-ping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhengyun Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoping Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Baorui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jia Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jia Wei.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Q., Yang, Y., Zhang, Yp. et al. Prognostic value of carbohydrate tumor markers and inflammation-based markers in metastatic or recurrent gastric cancer. Med Oncol 31, 289 (2014). https://doi.org/10.1007/s12032-014-0289-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0289-9

Keywords

Search

Navigation